Fostamatinib - Rigel Pharmaceuticals

Drug Profile

Fostamatinib - Rigel Pharmaceuticals

Alternative Names: FosD; Fostamatinib disodium; Fostamatinib disodium hexahydrate; Fostamatinib sodium; R 985788; R-406/788; R-788; R-935/788; R788 sodium; R935788 sodium; Tamatinib fosdium; Tavalisse

Latest Information Update: 30 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Rigel Pharmaceuticals
  • Developer AstraZeneca; Duke University Medical Center; Rigel Pharmaceuticals; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • Class Anti-inflammatories; Antianaemics; Antirheumatics; Oxazines; Phosphoric acid esters; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action Syk kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Autoimmune haemolytic anaemia; Idiopathic thrombocytopenic purpura
  • New Molecular Entity Yes
  • Available For Licensing Yes - IgA nephropathy

Highest Development Phases

  • Marketed Idiopathic thrombocytopenic purpura
  • Phase II Autoimmune haemolytic anaemia; IgA nephropathy
  • Phase I Graft-versus-host disease; Ovarian cancer
  • Discontinued Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Rheumatoid arthritis; Solid tumours; Systemic lupus erythematosus; T cell lymphoma; Type 1 diabetes mellitus

Most Recent Events

  • 29 May 2018 Launched for Idiopathic thrombocytopenic purpura (Treatment-experienced) in USA (PO) - First global launch
  • 17 Apr 2018 Rigel Pharmaceuticals expects to launch fostamatinib for Immune thrombocytopenic purpura in USA by late May 2018
  • 17 Apr 2018 Registered for Idiopathic thrombocytopenic purpura (Treatment-experienced) in USA (PO) - First global approval
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top